The Employment of Cancer Immunotherapy for Glioblastoma
DOI:
https://doi.org/10.58445/rars.1504Keywords:
cancer, glioblastoma, immunotherapy, cancer immunotherapy, Cancer, Glioblastoma, Biology, Cancer Immunotherapy, Immunotherapy, Clinical TrialsAbstract
This paper explores the potential of immunotherapy in treating glioblastoma, a severe form of brain cancer resistant to conventional treatments. Glioblastoma's unique characteristics, including its protective barriers and ability to evade the immune system, limit the effectiveness of immunotherapies. We discuss a variety of immunotherapies under investigation, such as dendritic cell-based therapies, immune checkpoint inhibitors, and CAR T-cell therapy. Despite promising results in clinical trials, their overall impact remains limited due to the complexities of glioblastoma. Future research focuses on developing more effective immunotherapies, exploring combination therapies, and overcoming treatment challenges. Immunotherapy holds significant potential in revolutionizing glioblastoma treatment, with continued research and innovation promising to improve survival rates and quality of life for patients battling this challenging disease.
References
Wirsching HG, Galanis E, Weller M. Glioblastoma. Handb Clin Neurol. 2016;134:381-97. doi: 10.1016/B978-0-12-802997-8.00023-2. PMID: 26948367.
Medikonda R, Dunn G, Rahman M, Fecci P, Lim M. A review of glioblastoma immunotherapy. J Neurooncol. 2021 Jan;151(1):41-53. doi: 10.1007/s11060-020-03448-1. Epub 2020 Apr 6. PMID: 32253714.
Yu MW, Quail DF. Immunotherapy for Glioblastoma: Current Progress and Challenges. Front Immunol. 2021 May 13;12:676301. doi: 10.3389/fimmu.2021.676301. Erratum in: Front Immunol. 2021 Oct 07;12:782687. doi: 10.3389/fimmu.2021.782687. PMID: 34054867; PMCID: PMC8158294.
Wirsching, H. G., & Weller, M. (2017). Glioblastoma. Malignant Brain Tumors: State-of-the-Art Treatment, 265-288.
Shergalis, A., Bankhead, A., Luesakul, U., Muangsin, N., & Neamati, N. (2018). Current challenges and opportunities in treating glioblastoma. Pharmacological reviews, 70(3), 412-445.
Yu, M. W., & Quail, D. F. (2021, April 21). Immunotherapy for glioblastoma: Current progress and challenges. Frontiers. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.676301/full
Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., Wang, A. C., Ellingson, B. M., Rytlewski, J. A., Sanders, C. M., Kawaguchi, E. S., Du, L., Li, G., Yong, W. H., Gaffey, S. C., Cohen, A. L., Mellinghoff, I. K., Lee, E. Q., Reardon, D. A., O'Brien, B. J., … Prins, R. M. (2019).
Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., Thor Straten, P., Martínez-Ricarte, F., Ponsati, B., Okada, H., Lassen, U., Admon, A., Ottensmeier, C. H., Ulges, A., Kreiter, S., von Deimling, A., … Wick, W. (2019). Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature, 565(7738), 240–245. https://doi.org/10.1038/s41586-018-0810-y
Clinicaltrials.gov (n.d.). https://www.clinicaltrials.gov/study/NCT01280552
Brown, C. E., Rodriguez, A., Palmer, J., Ostberg, J. R., Naranjo, A., Wagner, J. R., Aguilar, B., Starr, R., Weng, L., Synold, T. W., Tran, V., Wang, S., Reik, A., D'Apuzzo, M., Ressler, J. A., Zhou, Y., Mendel, M., Gregory, P. D., Holmes, M. C., Tang, W. W., … Badie, B. (2022). Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma. Neuro-oncology, 24(8), 1318–1330. https://doi.org/10.1093/neuonc/noac024
Salvato, I., & Marchini, A. (2024). Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives. Cancers 2024, 16, 1276.
Clinicaltrials.gov (n.d.). https://www.clinicaltrials.gov/study/NCT04396860
Downloads
Posted
Categories
License
Copyright (c) 2024 Sahil Dutta
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.